PRESS RELEASE: Publication of the annual report 2012 of BB Biotech AG

BB BIOTECH AG / Publication of the annual report 2012 of BB Biotech AG . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Today BB Biotech AG is publishing its annual report for the past fiscal year.

For further information: Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland Dr. Silvia Schanz, tel +41 44 267 72 66, ssc@bellevue.ch Claude Mikkelsen, tel +41 44 267 67 26, cmi@bellevue.ch www.bbbiotech.com

Company profile BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with CHF 1.3 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Annual report 2012 (PDF): http://hugin.info/130285/R/1679776/548628.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: BB BIOTECH AG via Thomson Reuters ONE [HUG#1679776]

--- End of Message ---

BB BIOTECH AG Vordergasse 3 Schaffhausen Switzerland

WKN: AONFN3;ISIN: CH0038389992;

(END) Dow Jones Newswires

   February 21, 2013 01:01 ET (06:01 GMT)- - 01 01 AM EST 02-21-13